Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects identifying their main symptom as a burning feeling in the mid epigastric area and/or chest area (ie, heartburn).~* Subject has a history of episodes of heartburn for 6 months or longer prior to Screening.~* Subject must have a history of episodes of heartburn for 4 or more days during the 7 days prior to Day -1.~Exclusion Criteria:~* Endoscopic Barrett's esophagus and/or definite dysplastic changes. History of dilatation of esophageal strictures.~* Subjects with erosive esophagitis (EE) as shown by endoscopy.~* Evidence of uncontrolled systemic disease. Co-existing diseases affecting the esophagus. Current or history of Zollinger-Ellison syndrome.~* Subject has abnormal laboratory values.~* Subjects with active gastric or duodenal ulcers within 4 weeks of the first dose.~* Subject known to have acquired immunodeficiency syndrome (AIDS).~* Known hypersensitivity to any proton pump inhibitor (PPI), any component of Dexlansoprazole MR, or antacid.~* Use of prescription or non-prescription PPIs, histamine (H2) receptor antagonists, or sucralfate.~* Chronic (\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors.~* Use of antacids (except for study-supplied Gelusil® ).~* Use of drugs with significant anticholinergic effects.~* Subjects who cannot discontinue the use of misoprostol or prokinetics~* Need for continuous anticoagulant therapy.~* Females who are pregnant or lactating.~* History of gastrointestinal surgery except for simple oversew of ulcer.~* History of cancer within 3 years prior to screening.~* Subject has participated in a previous Dexlansoprazole study.~* Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 30 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).